Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for those with Type 2 diabetes. The system ...

Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to ...

The revised price target comes as Thibault anticipates a boost in U.S. sales of the Omnipod insulin management system, particularly in the second half of 2025, due to expanded marketing efforts ...

Intuitive Surgical (ISRG), and Insulet (PODD) stocks were cited as top MedTech stock picks for 2025 by J.P. Morgan. Read more ...

The revised price target comes as Thibault anticipates a boost in U.S. sales of the Omnipod insulin management system, particularly in the second half of 2025, due to expanded marketing efforts aimed ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of ...

BTIG analyst Marie Thibault maintained a Buy rating on Insulet (PODD – Research Report) today and set a price target of $300.00. The company’s ...

Surreal” is how Kelsey Bascom describes her journey with Type 1 diabetes. That about covers how the actor and filmmaker went ...

In December, a Massachusetts corporation won the largest jury verdict ever awarded under the federal Defend Trade Secrets Act ...

Ozempic's ads were 57% more effective in driving consumer engagement on streaming TV than on linear TV during Q3.